Gazyva obinutuzumab: Phase Ib data

The open-label, international Phase Ib GAUDI trial in 81 treatment-naïve patients with B cell follicular NHL showed that obinutuzumab plus Treanda bendamustine and obinutuzumab plus CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisone) led to complete response (CR) rates of 37% and 35%, respectively, at the end of induction treatment period. At the end of the maintenance treatment period, the CR rates increased to 61% in patients receiving obinutuzumab plus Treanda and to 70% in patients receiving obinutuzumab plus CHOP chemotherapy. The PFS rate at 32 months was 92% in the obinutuzumab plus Treanda arm and 84% in the obinutuzumab plus CHOP chemotherapy arm. During the induction period, patients received 1,000 mg IV obinutuzumab plus Treanda or CHOP chemotherapy in 3-week cycles for 6-8 cycles. Patients who responded to induction treatment (n=72) then received maintenance treatment with obinutuzumab plus Treanda or CHOP chemotherapy every 3 months for 2 years or until disease progression. Data were presented at the American Society of Hematology meeting in San Francisco. ...